Modular Nanoparticle Vaccine Compositions for Targeted Immune Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine technologies face challenges in effectively delivering antigens to immune cells, particularly in eliciting cell-mediated immunity and mucosal immunity, and are limited by the use of traditional adjuvants which can have risks and inefficiencies, especially for diseases like malaria and HIV, where vaccines are poorly developed or unavailable.
Innovation Solution
Development of modular nanoparticle vaccine compositions that encapsulate antigens and adjuvants, allowing for targeted delivery to specific immune cells through surface modification with targeting molecules, enabling flexible composition and enhanced immune response modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants are used to amplify immune response, then immune stimulation is enhanced, but risks of deleterious inflammatory responses and allergic side effects increase
Solution Approach 1:
The vaccine system is segmented into distinct functional modules: antigen delivery nanoparticles and separate adjuvant nanoparticles. This allows independent optimization of each component's safety and efficacy, enabling precise control over immune stimulation while minimizing harmful effects through modular design.
Solution Approach 2:
The patent introduces nanoparticles as intermediary carriers that mediate the interaction between adjuvants and the immune system. These nanoparticles control the release and delivery of adjuvant molecules, acting as a buffer that reduces direct harmful effects while maintaining immune stimulation effectiveness.
2Ease of manufacture
If purified antigen subunits are used, then production safety and scalability are improved, but immunogenicity decreases compared to whole pathogens
Solution Approach 1:
The patent merges purified antigen subunits with adjuvant-loaded nanoparticles to create a composite vaccine formulation. This combination restores the immunogenicity lost in purified forms by presenting the antigen in a context that mimics whole pathogen structures, while maintaining the safety and scalability of recombinant production methods.
Solution Approach 2:
The vaccine employs composite nanoparticle structures combining multiple materials and functional elements. These composite nanoparticles present purified antigens in a modified structural context that enhances their immunogenicity while preserving the advantages of recombinant production safety and scalability.
3Reliability
If adjuvants are co-administered with antigens, then immune response is potentiated, but delivery control and selectivity to target cells are limited
Solution Approach 1:
The vaccine system segments antigen delivery and adjuvant delivery into separate nanoparticle components. This allows independent control over the delivery parameters of each component, enabling precise targeting to specific immune cells and tissues while maintaining effective immune potentiation through their controlled interaction.
Solution Approach 2:
The patent employs dynamic control mechanisms in the nanoparticle formulation, including pH-responsive release and enzymatic triggers, that allow the adjuvant and antigen to be released in a controlled sequence upon reaching target cells. This dynamic delivery control enhances both immune response potentiation and delivery selectivity.
4Device complexity
If conventional vaccine formulations are used, then manufacturing simplicity is maintained, but ability to induce cell-mediated and mucosal immunity is insufficient
Solution Approach 1:
The vaccine formulation is segmented into multiple functional nanoparticle components, each designed for specific functions: antigen presentation, adjuvant delivery, and immune cell targeting. This segmentation enables the induction of cell-mediated and mucosal immunity while maintaining manufacturing simplicity through standardized nanoparticle production protocols.
Solution Approach 2:
The nanoparticle platform is designed with multi-functionality, serving as both an antigen delivery vehicle and an adjuvant carrier, and capable of targeting multiple immune cell types. This universal design enables the induction of diverse immune responses including cell-mediated and mucosal immunity while maintaining formulation simplicity through a single platform approach.
Data Source
AI summary
Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and subtraction of antigen, adjuvant, immune potentiators, molecular recognition and transport mediation elements, as well as intracellular uptake mediators, allows for exquisite control over variables that are important in optimizing an effective vaccine delivery system.